COVID-19: Oxford University In New Vaccine Breakthrough,Distribution possible in Few Months



Hopes of getting a coronavirus vaccine grew today after Oxford University’s jab was found to be safe and provoke an immune reaction that lasts for at least two months.

Hugely-anticipated clinical trial results revealed almost 100 per cent of volunteers given the jab produced an immune response against the coronavirus.


In a sub-group of 35 participants out of 477, between 33 and 35 of them still had a ‘neutralising’ response – meaning their body may be able to prevent Covid-19 – after a month. Immune responses remained strong for at least 56 days, researchers said.

This means that there were strong signs in their blood that they could fight off the coronavirus if they were to catch it, but this has not yet been proven.

Crucially, nobody has had any bad side effects from the vaccine and it is stimulating the immune system as scientists hoped it would.

Some people developed headaches, tiredness and pain in their arm after they were given the jab, but none of the side effects were severe, scientists said.

The Oxford vaccine is already being manufactured by AstraZeneca, based in Cambridge, and the UK Government has ordered 100million doses ahead of time.

One of the researchers on the project said ‘these early results hold promise’ but added: ‘There is still much work to be done’.

The eagerly awaited results come after Prime Minister Boris Johnson this morning tried to temper expectations when he admitted he wasn’t totally confident there would even be a vaccine by the end of next year.

Ministers did, however, today announce deals for a further 90million doses of two types of experimental jab being developed in France and Germany.

Britain is shoring up stocks of vaccines in development all over the world in its spread-betting approach in the hope that at least one of them will pay off.

The university published the findings from its most recent trials of the vaccine in the medical journal the Lancet. The Oxford team reported no early safety concerns from the vaccine and said it produced a strong immune response.

“The vaccine provoked a T cell response within 14 days of vaccination (white blood cells that can attack cells infected with the SARS-CoV-2 virus), and an antibody response within 28 days (antibodies are able to neutralise the virus so that it cannot infect cells when initially contracted),” the university said in a statement about the findings.

Dr Anthony Fauci, the US government’s top infectious disease expert, has said he thinks it is likely a vaccine will be developed by early next year, but Trump has suggested (without much basis) that a vaccine could be developed even faster.

Leave a Reply

Your email address will not be published. Required fields are marked *